Hyonate packshot
Anti-Inflammatory Strengthens Merial Equine Range
The anti-inflammatory treatment for lameness in horses, Hyonate® (sodium hyaluronate), has been purchased by Merial Animal Health, the company has announced.
Adding to Merial’s equine portfolio, Hyonate® is an established treatment of lameness in horses due to non-infectious inflammation of joints, using both intra-articular (IA) and intravenous (IV) injection, says Merial’s equine marketing and technical manager, Louise Radford MRCVS.
Delighted with the addition to the equine range, Louise explains that as a major cause of decreased performance in horses, joint dysfunction can develop from repeated episodes of trauma that horses can experience in everyday work or competition.
Joining Equioxx®, the first COX-2 specific NSAID for horses, the addition of Hyonate® provides equine vets with a choice of treatments for inflammation and joint disease from the company.
“The beneficial effects of HA supplementation are attributable to the anti-inflammatory effects, improvement in viscoelastic properties of the synovial fluid, and interaction with the synovial membrane affecting pain transmission and joint metabolism¹,” adds Louise.
Hyonate® joins Merial’s portfolio of market leading equine products including the UK’s first anti-ulcer prescription medicine GastroGard® (omeprazole), ProteqFlu® vaccines, the first and only in Europe to contain the most recent Florida Clade 1 and clade 2 strains, and tried and trusted wormers, Eqvalan® (ivermectin) and Eqvalan® Duo (ivermectin+ praziquantel).
For more information telephone Customer Support on 0870 6000123 or contact your local Merial Equine Specialist.
More from Merial Animal Health
- Survey Says Pet Parasite Action Campaign Was A Success
- Merial And Bvna Launch Parasitxpert Free Cpd And Award
- Vets Unite Behind Pet Parasite Action Campaign
- Nexgard Spectra Becomes The Only Product Licensed To Prevent Lungworm And Kill Ticks
- Free webinar considers risks from Toxocara to human and animal health